Author(s):
Dedy Budi Kurniawan, Mokhamad Fahmi Rizki Syaban, Arinal Mufidah, Muhammad Unzila Rafsi Zulfikri, Wibi Riawan
Email(s):
mokhamadfahmi@gmail.com
DOI:
10.52711/0974-360X.2021.01006 
Address:
Dedy Budi Kurniawan1, Mokhamad Fahmi Rizki Syaban2, Arinal Mufidah2, Muhammad Unzila Rafsi Zulfikri2, Wibi Riawan3
1Mastes of Biomedical Science Program, Faculty of Medicine, Universitas Brawijaya, Malang, Indonesia.
2Undergraduated Student, Faculty of Medicine, Universitas Brawijaya, Malang, Indonesia.
3Department of Biochemistry, Faculty of Medicine, Universitas Brawijaya, Malang, Indonesia.
*Corresponding Author
Published In:
Volume - 14,
Issue - 11,
Year - 2021
ABSTRACT:
Stroke is one of the leading causes of morbidity and mortality in all ages. Ischemic stroke activates excitotoxic glutamate cascade leading to brain tissue injury. Saccharomyces cerevisiae is a unicellular yeast widely found in nature. S. cerevisiae is neuroprotective and able to increase the differentiation of hematopoietic stem cells (HSCs) into neuronal cells. it may increase levels of neuroprotectant BDNF in the brain tissue, therefore increase the protection of neurons. BDNF may prevent glutamate-driven excitotoxicity by reducing glutamate levels. This study uses a randomized post-test only controlled group design. In this in vivo study, rodent models of ischemic stroke were divided into five groups comprising of the negative control group, positive control group, intervention group 1 (18mg/kgBW), intervention group 2 (36mg/kgBW) and intervention group 3 (72 mg/kgBW). Groups treated with Saccharomyces cerevisiae extract showed significantly increased BDNF levels in the brain tissue, and the expression of the glutamate level was significantly reduced (P <0.05) compared to the positive control group. Thus Saccharomyces cerevisiae has a promising potential to become a therapy against ischemic stroke disease. however further research is needed regarding the efficacy and toxicity of Saccharomyces cerevisiae.
Cite this article:
Dedy Budi Kurniawan, Mokhamad Fahmi Rizki Syaban, Arinal Mufidah, Muhammad Unzila Rafsi Zulfikri, Wibi Riawan. Protective effect of Saccharomyces cerevisiae in Rattus norvegicus Ischemic Stroke Model. Research Journal of Pharmacy and Technology. 2021; 14(11):5785-9. doi: 10.52711/0974-360X.2021.01006
Cite(Electronic):
Dedy Budi Kurniawan, Mokhamad Fahmi Rizki Syaban, Arinal Mufidah, Muhammad Unzila Rafsi Zulfikri, Wibi Riawan. Protective effect of Saccharomyces cerevisiae in Rattus norvegicus Ischemic Stroke Model. Research Journal of Pharmacy and Technology. 2021; 14(11):5785-9. doi: 10.52711/0974-360X.2021.01006 Available on: https://rjptonline.org/AbstractView.aspx?PID=2021-14-11-31
REFERENCES:
1. Kim H-S, Lee K-C, Bae W-S. The Effects of Stepping Exercises on a Box or Stairs on Stroke Patients Lower Limb Muscle Activity and Balance. Rese Jour of Pharm and Technol. 2018;11(4):1289.
2. Ali DKA. Quality of Life of Patients with Ischemic Stroke versus Hemorrhagic Stroke: Comparative Study. Rese Jour of Pharm and Technol. 2018;11(11):4911.
3. Dave K, Singh N. Knowledge Among Stroke and High Risk Patients Regarding Risk Factors, Warning Signs and Immediate Treatment of Stroke. Inter Jour of Adva in Nur Manag. 2016;4(4):331.
4. Ma S-R, Yang B-I. The Effects of Scapula Setting Intervention on the ADL and gait in the Stroke Patients. Rese Jour of Pharm and Technol. 2018;11(7):2792.
5. Durukan A, Tatlisumak T. Acute ischemic stroke: overview of major experimental rodent models, pathophysiology, and therapy of focal cerebral ischemia. Pharmacology Biochemistry and Behavior. 2007 May 1;87(1):179-97.
6. Thomas P, Jeyarani SV, Choephel T, Manisha C, Antony J. Recent Plant Based Remedies for Alzheimer’s Disease, Parkinson’s Disease and Cerebral Ischemic Stroke. Rese Jour of Pharm and Technol. 2019;12(8):3951.
7. Gomes, C., Ferreira, R., George, J., Sanches, R., Rodrigues, D.I., Gonçalves, N. and Cunha, R.A., 2013. Activation of microglial cells triggers a release of brain-derived neurotrophic factor (BDNF) inducing their proliferation in an adenosine A 2A receptor-dependent manner: A 2A receptor blockade prevents BDNF release and proliferation of microglia. Journal of neuroinflammation, 10(1), p.780.
8. Ranjan S, Sharma PK. Association of Brain-Derived Neurotrophic factor (BDNF) gene SNP G196A with Type 2 Diabetes and Obesity: A Meta-Analysis. Rese Jour of Pharm and Technol. 2017;10(12):4297.
9. Kim T-G, Bae S-H, Kim K-Y. Effects of Dual-Task Training with different Intensity of Aerobic Exercise on Cognitive Function and Neurotrophic Factors in Chronic Stroke Patients. Rese Jour of Pharm and Technol. 2019;12(2):693.
10. Brkich GE, Pyatigorskaya NV, Demina NB, Zyryanov OA, Krasnyuk II. Scientific and Methodical approach to developing the formulation of an Innovative Medicinal Product based on a derivative of 3, 7-diazabicyclo [3.3.1]nonane (hydrindane). Rese Jour of Pharm and Technol. 2019;12(12):5752.
11. Cramer DE, Wagner S, Li B, Liu J, Hansen R, Reca R, Wu W, Surma EZ, Laber DA, Ratajczak MZ, Yan J. Mobilization of Hematopoietic Progenitor Cells by Yeast‐Derived β‐Glucan Requires Activation of Matrix Metalloproteinase‐9. Stem Cells. 2008 May;26(5):1231-40.
12. Engel O, Kolodziej S, Dirnagl U, Prinz V. Modeling stroke in mice-middle cerebral artery occlusion with the filament model. JoVE (Journal of Visualized Experiments). 2011 Jan 6(47):e2423.
13. Larson-Hall J. A guide to doing statistics in second language research using SPSS and R. Routledge; 2015 Jul 24.
14. Nelson ED, Ramberg JE, Best T, Sinnott RA. Neurologic effects of exogenous saccharides: a review of controlled human, animal, and in vitro studies. Nutritional neuroscience. 2012 Jul 1;15(4):149-62.
15. Bayas A, Hummel V, Kallmann BA, Karch C, Toyka KV, Rieckmann P. Human cerebral endothelial cells are a potential source for bioactive BDNF. Cytokine. 2002 Jul 1;19(2):55-8.
16. Lai AY, Todd KG. Differential regulation of trophic and proinflammatory microglial effectors is dependent on severity of neuronal injury. Glia. 2008 Feb;56(3):259-70.
17. Chan GC, Chan WK, Sze DM. The effects of β-glucan on human immune and cancer cells. Journal of hematology & oncology. 2009 Dec;2(1):25.
18. Hauk TG, Leibinger M, Müller A, Andreadaki A, Knippschild U, Fischer D. Stimulation of axon regeneration in the mature optic nerve by intravitreal application of the toll-like receptor 2 agonist Pam3Cys. Investigative ophthalmology & visual science. 2010 Jan 1;51(1):459-64.
19. Di Lazzaro V, Profice P, Pilato F, Dileone M, Florio L, Tonali PA, Angelucci F. BDNF plasma levels in acute stroke. Neuroscience letters. 2007 Jul 11;422(2):128-30.
20. Béjot Y, Mossiat C, Giroud M, Prigent-Tessier A, Marie C. Circulating and brain BDNF levels in stroke rats. Relevance to clinical studies. PloS one. 2011 Dec 16;6(12):e29405.
21. Koroleva ES, Tolmachev IV, Alifirova VM, Boiko AS, Levchuk LA, Loonen AJ, Ivanova SA. Serum BDNF’s Role as a Biomarker for Motor Training in the Context of AR-Based Rehabilitation after Ischemic Stroke. Brain Sciences. 2020 Sep;10(9):623.
22. Mahendran R, Jeyabasker S, Francis A, Manoharan S. Homology Modeling and in silico docking analysis of BDNF in the treatment of Alzheimer’s disease. Rese Jour of Pharm and Technol. 2017;10(9):2899.
23. Malik A, Malik N, Dhiman P, Khatkar A, Kakkar S. Molecular docking, synthesis, α-amylase inhibition, urease inhibition and antioxidant evaluation of 4-hydroxy-3-methoxy benzoic acid derivatives. Rese Jour of Pharm and Technol. 2019;12(12):5653.
24. Shirley R, Ord EN, Work LM. Oxidative stress and the use of antioxidants in stroke. Antioxidants. 2014 Sep;3(3):472-501.
25. Anurogo D, Ikrar T. The Neuroscience of Glutamate. Ethical Digest. 2014;120:55-61.
26. Choi DW, Koh JY, Peters S. Pharmacology of glutamate neurotoxicity in cortical cell culture: attenuation by NMDA antagonists. Journal of Neuroscience. 1988 Jan 1;8(1):185-96.